Bristol-Myers Squibb Executive and Leadership Team

Tomas Bohman, the Global Chief Financial Officer, Research & Senior VP, Development, Finance at Bristol-Myers Squibb, directs all financial operations supporting the company's extensive research and development endeavors. This executive role is central to allocating capital effectively across diverse therapeutic domains, including oncology, cardiovascular disease, and virology, ensuring that investments align with strategic priorities for discovering and developing new medications. Bohman's financial leadership guides resource management for groundbreaking scientific initiatives, from early-stage discovery through late-stage clinical development. The position demands a comprehensive understanding of the biopharmaceutical R&D lifecycle and its associated financial complexities. By overseeing financial strategy for research and development, Tomas Bohman plays a crucial part in Bristol-Myers Squibb's ability to bring innovative treatments to patients and maintain its position as a leader in addressing serious unmet medical needs. This executive's financial acumen is indispensable for driving scientific progress.

Bud Glogovac, the Director, Finance (Country & Chief Financial Officer at Bristol-Myers Squibb, manages critical financial operations and strategic fiscal planning for specific country markets and broader financial functions. This executive role is integral to ensuring financial health and compliance across diverse geographical regions where Bristol-Myers Squibb operates, supporting the company's mission to deliver essential medications globally. Glogovac's responsibilities include overseeing budgeting, forecasting, and financial reporting, ensuring alignment with corporate financial objectives and regulatory requirements. The position requires a nuanced understanding of international financial markets and local economic conditions to optimize financial performance and resource allocation. By providing expert financial direction, Bud Glogovac directly contributes to Bristol-Myers Squibb's sustained growth and its capacity to invest in research and development for life-saving therapies. This executive's financial stewardship is vital for the company's global operational success.

Umang Srivastava, the Strategy Director, Transformation & Gps Chief of Staff at Bristol-Myers Squibb, directs strategic initiatives focused on organizational transformation and operational efficiency within the Global Product and Supply (GPS) division. This leadership position involves architecting and implementing key strategic projects that enhance the company's ability to deliver life-saving medications to patients worldwide. Srivastava's responsibilities include fostering cross-functional collaboration to align departmental goals with overarching corporate objectives, ensuring that strategic plans translate into tangible operational improvements. The role demands a deep understanding of the biopharmaceutical landscape, particularly in oncology, cardiovascular disease, and virology, to guide strategic decision-making. By overseeing critical transformation efforts, Umang Srivastava ensures that Bristol-Myers Squibb maintains its competitive edge and continues to meet significant unmet medical needs through its comprehensive medication portfolio. This executive's focus on strategic execution drives the company's mission forward, optimizing resource allocation and accelerating the development of new therapeutic solutions.

Scott Trautwein, the Manager, Chief Technology Officer MSAT Process Validation at Bristol-Myers Squibb, oversees critical technology functions related to manufacturing science and technology (MSAT) process validation. This role is pivotal in ensuring the integrity and reliability of manufacturing processes for the company's diverse portfolio of prescription medications, including those for oncology and cardiovascular disease. Trautwein's leadership ensures that all validation activities adhere to stringent regulatory standards and internal quality protocols, safeguarding product quality and patient safety. The scope of this position involves managing teams responsible for the technical validation of complex biopharmaceutical manufacturing processes, particularly those involving advanced therapies. By driving robust process validation strategies, Scott Trautwein directly contributes to the company's operational excellence and its capacity to consistently supply innovative treatments to patients globally. This executive's technical oversight is fundamental to maintaining Bristol-Myers Squibb's reputation for quality and efficacy in the biopharmaceutical sector.

Nicole Costa, the Cell Therapy Development & Operations Chief of Staff at Bristol-Myers Squibb, directs critical operational and developmental functions within the company's advanced cell therapy programs. This executive role is central to accelerating the discovery, development, and scaling of innovative cell therapies, particularly in the oncology domain. Costa's responsibilities encompass ensuring seamless integration between research and development efforts and manufacturing operations, optimizing the pathway from laboratory breakthroughs to patient delivery. The position requires a strategic approach to managing complex operational workflows and fostering collaboration across diverse scientific and technical teams. By providing operational leadership and strategic support, Nicole Costa enhances the efficiency and effectiveness of cell therapy initiatives, directly impacting the company's ability to address serious patient needs in cancer treatment. This executive's dedication to operational excellence in cell therapy development is crucial for Bristol-Myers Squibb's leadership in this cutting-edge therapeutic area.

John Van Oostendorp, the Manager, Chief Technology Officer Site Supply Chain Compliance at Bristol-Myers Squibb, leads critical technology initiatives focused on ensuring compliance within the company's global supply chain operations. This executive role is essential for maintaining the integrity and regulatory adherence of the entire supply chain, from raw material sourcing to final product distribution across various therapeutic areas like oncology and virology. Van Oostendorp's oversight ensures that technology systems supporting the supply chain meet all applicable industry standards and governmental regulations, thereby safeguarding product quality and patient access. The position involves managing technology solutions that enhance visibility, traceability, and security throughout the supply chain network. By driving robust compliance strategies, John Van Oostendorp directly supports Bristol-Myers Squibb's commitment to operational excellence and its mission to deliver essential medications reliably to patients worldwide. This executive's focus on compliance is fundamental to the company's sustained success.

Joshua Sugrim, the Manager, Chief Technology Officer MSAT Process Validation - CAR T Cell Therapy at Bristol-Myers Squibb, spearheads critical technology management for the validation of CAR T cell therapy manufacturing processes. This executive role is paramount in ensuring the consistent quality and efficacy of advanced cell therapies, a key focus for the company in treating complex cancers. Sugrim's leadership ensures that all validation protocols for CAR T therapies meet rigorous scientific and regulatory requirements, supporting the safe and effective delivery of these innovative treatments to patients. The position involves deep technical expertise in biopharmaceutical manufacturing and process validation, specifically within the highly specialized field of cell therapy. By driving meticulous validation efforts, Joshua Sugrim directly contributes to Bristol-Myers Squibb's leadership in CAR T cell therapy development and its capacity to scale these life-changing treatments. This executive's commitment to technical excellence is vital for the company's ongoing success in oncology.

Debra Golding, the Senior Executive Associate, Chief of Staff and Compliance at Bristol-Myers Squibb, provides critical support and oversight for the company's compliance initiatives and executive operations. This role is essential in ensuring that all business activities adhere to the highest ethical standards and regulatory requirements across the biopharmaceutical sector. Golding's responsibilities include coordinating compliance programs, managing executive communications, and facilitating the smooth execution of strategic projects that uphold the company's integrity. The position demands a thorough understanding of pharmaceutical regulations and corporate governance principles. By ensuring robust compliance frameworks and supporting executive functions, Debra Golding directly contributes to Bristol-Myers Squibb's commitment to responsible business practices and its mission to address serious patient needs with trustworthy medications. This executive's dedication to compliance reinforces the company's reputation for quality and ethical conduct.

Kimberly Kam, the Senior Specialist, Chief Technology Officer MSAT Process Validation Engineer II at Bristol-Myers Squibb, executes critical technical validation processes within the manufacturing science and technology (MSAT) division. This role is fundamental to ensuring the reliability and compliance of manufacturing processes for the company's diverse range of prescription medications, including those for oncology and cardiovascular disease. Kam's engineering expertise is applied to validating complex production methods, ensuring adherence to stringent quality standards and regulatory mandates. The position involves detailed analysis and documentation of process validation studies, contributing directly to product integrity and patient safety. By meticulously performing validation engineering tasks, Kimberly Kam supports Bristol-Myers Squibb's operational excellence and its ability to consistently deliver high-quality therapeutic solutions to patients worldwide. This executive's technical contributions are vital for maintaining manufacturing standards.

Divya Sahdev, the Senior Director, Governance and Portfolio Operations, GPS Chief of Staff at Bristol-Myers Squibb, directs key governance structures and portfolio operations within the Global Product and Supply (GPS) organization. This executive role is crucial for ensuring that the company's operational portfolio aligns with strategic objectives and maintains the highest standards of governance. Sahdev's responsibilities include overseeing portfolio management processes, implementing robust governance frameworks, and driving operational efficiencies across GPS functions. The position requires a strategic understanding of the biopharmaceutical supply chain and product development lifecycle to effectively manage diverse projects and initiatives. By enhancing governance and optimizing portfolio operations, Divya Sahdev directly supports Bristol-Myers Squibb's mission to deliver innovative medications to patients globally and maintain operational excellence. This executive's leadership is vital for strategic execution and resource management.